Literature DB >> 11239949

A novel missense mutation in the early growth response 2 gene associated with late-onset Charcot--Marie--Tooth disease type 1.

T Yoshihara1, F Kanda, M Yamamoto, H Ishihara, K Misu, N Hattori, K Chihara, G Sobue.   

Abstract

A novel mutation (Arg381Cys) in the second zinc-finger domain of early growth response 2 (EGR2) was identified in a late-onset Charcot--Marie--Tooth disease type 1 (CMT1) patient. This patient had initial symptoms of numbness and weakness in the leg at age 59, and a median nerve motor conduction velocity of 27 m/s. A sural nerve biopsy showed a severe loss of myelinated fibers with numerous onion bulbs. This is the first report of the EGR2 mutation presenting a late onset of CMT1 phenotype. Its mutation was a different amino acid substitution at codon 381 (Arg381His) which demonstrated congenital hypomyelinating neuropathy or early-onset CMT1. This report suggests that the EGR2 mutation represents divergent phenotypes at codon 381, which may be a mutation hotspot.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11239949     DOI: 10.1016/s0022-510x(00)00504-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

1.  Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.

Authors:  Tomonori Nakamura; Akihiro Hashiguchi; Shinsuke Suzuki; Kimiharu Uozumi; Shoko Tokunaga; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-01-25       Impact factor: 2.660

2.  Current Therapy for Charcot-Marie-Tooth Disease.

Authors:  Marina Grandis; Michael E Shy
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.598

Review 3.  A review of genetic counseling for Charcot Marie Tooth disease (CMT).

Authors:  Carly E Siskind; Seema Panchal; Corrine O Smith; Shawna M E Feely; Joline C Dalton; Alice B Schindler; Karen M Krajewski
Journal:  J Genet Couns       Date:  2013-04-21       Impact factor: 2.537

Review 4.  Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease.

Authors:  O Dubourg; H Azzedine; C Verny; G Durosier; N Birouk; R Gouider; M Salih; A Bouhouche; A Thiam; D Grid; M Mayer; M Ruberg; M Tazir; A Brice; E LeGuern
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 5.  Molecular genetics of autosomal-dominant demyelinating Charcot-Marie-Tooth disease.

Authors:  Henry Houlden; Mary M Reilly
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

6.  Functional, histopathologic and natural history study of neuropathy associated with EGR2 mutations.

Authors:  Kinga Szigeti; Wojciech Wiszniewski; Gulam Mustafa Saifi; Diane L Sherman; Norbert Sule; Adekunle M Adesina; Pedro Mancias; Sozos Ch Papasozomenos; Geoffrey Miller; Laura Keppen; Donna Daentl; Peter J Brophy; James R Lupski
Journal:  Neurogenetics       Date:  2007-08-24       Impact factor: 2.660

7.  Progesterone derivatives increase expression of Krox-20 and Sox-10 in rat Schwann cells.

Authors:  Valerio Magnaghi; Marinella Ballabio; Ilaria Roglio; Roberto C Melcangi
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

8.  Disruption of Krox20-Nab interaction in the mouse leads to peripheral neuropathy with biphasic evolution.

Authors:  Anne Desmazières; Laurence Decker; Jean-Michel Vallat; Patrick Charnay; Pascale Gilardi-Hebenstreit
Journal:  J Neurosci       Date:  2008-06-04       Impact factor: 6.167

Review 9.  Charcot-Marie-Tooth disease and intracellular traffic.

Authors:  Cecilia Bucci; Oddmund Bakke; Cinzia Progida
Journal:  Prog Neurobiol       Date:  2012-03-22       Impact factor: 11.685

Review 10.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.